利妥昔单抗治疗难治性疱疹样皮炎
本文报告一例80余岁男性疱疹样皮炎患者,经无麸质饮食(依从性差)、氨苯砜及常规免疫抑制剂治疗均未控制,按淋巴瘤方案接受利妥昔单抗(每周4次输注,375 mg/m2)后,瘙痒及临床表现完全缓解,抗表皮和抗组织转谷氨酰胺酶抗体正常化,治疗后18个月仍无症状。作者提出利妥昔单抗可作为难治性疱疹样皮炎的治疗选择。
要点
- 利妥昔单抗按淋巴瘤方案(4次每周375 mg/m2)用于难治性疱疹样皮炎。
- 无复发生存至治疗后18个月,提示利妥昔单抗为难治性疱疹样皮炎可行选择。
核心结论
- 利妥昔单抗可能作为难治性疱疹样皮炎的可行治疗选择。
研究设计与样本
- 单例病例报告:80余岁男性疱疹样皮炎患者,对无麸质饮食(依从性差)、氨苯砜及常规免疫抑制剂治疗无效。
主要发现
- 抗表皮转谷氨酰胺酶和抗组织转谷氨酰胺酶抗体均正常化。
- 治疗后18个月仍无症状,达到完全临床和血清学缓解。
关键数值与推荐
- 利妥昔单抗给药方案:4次每周输注,每次375 mg/m2(淋巴瘤方案)。
临床怎么用
- 对无麸质饮食、氨苯砜及常规免疫抑制剂治疗无效的疱疹样皮炎,可考虑利妥昔单抗。
- 利妥昔单抗可能实现临床和血清学双重缓解,需监测抗体和症状。
局限性
- 仅单例病例报告,证据级别低,结论需更多研究验证。
- 患者无麸质饮食依从性差,可能影响对治疗效果的归因。
- 随访时间有限(18个月),长期疗效和安全性未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Dermatitis herpetiformis (DH) is an autoimmune blistering condition seen in the context of celiac disease. While typically managed by gluten-free diet and dapsone, treatment of DH refractory to standard treatments is not well defined. OBSERVATIONS: A man in his 80s with DH not controlled by gluten-free diet (with poor adherence), dapsone, and conventional immune-suppressing agents responded to treatment with rituximab according to the lymphoma protocol (4 weekly infusions of 375 mg/m2). Thirteen months after treatment, the patient had achieved complete resolution of pruritus and clinical manifestations of the disease, as well as normalization of antibodies against epidermal and tissue transglutaminases. He achieved complete clinical and serological remission and has remained symptom-free up to 18 months following treatment. CONCLUSIONS AND RELEVANCE: We present here the first case of a patient with DH treated with rituximab who achieved complete clinical and serological remission. We suggest rituximab as a viable treatment option for recalcitrant DH.
引用
- Albers LN, Zone JJ, Stoff BK, et al. Rituximab Treatment for Recalcitrant Dermatitis Herpetiformis. JAMA Dermatol. 2017. PMID: 28030659. doi:10.1001/jamadermatol.2016.4676
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。